Future

2024

Million

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noreferrer noopener" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div> 
<p class="has-drop-cap">Moderna Inc. (NASDAQ: MRNA) showcased a resilient <a href="https://investors.modernatx.com/news/news-details/2024/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results-and-Provides-Business-Updates/default.aspx" target="_blank" aria-label="fourth-quarter performance (opens in a new tab)" rel="noreferrer noopener nofollow" class="deco-link">fourth-quarter performance</a> for the fiscal year 2023, navigating through the challenges posed by the transition to an endemic market environment. The biotechnology firm reported a robust revenue of $2.8 billion, a GAAP net income of $217 million, and a diluted earnings per share (<a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="dofollow" class="deco-link">EPS</a>) of $0.55. <br><br>This financial achievement underscores the company’s effective adaptation and strategic advancements across its diversified portfolio, including infectious diseases, oncology, and rare diseases. Despite declining COVID-19 vaccine sales, Moderna has capitalized on its commercial strategies to enhance its market share within the U.S., reflecting a proactive response to the evolving healthcare landscape.</p> 
<h3 id="moderna-posts-surprising-profit-in-q4-despite-declining-covid-19-vaccine-sales">Moderna Posts Surprising Profit in Q4 Despite Declining COVID-19 Vaccine Sales</h3> 
<p>When juxtaposed with the pre-established expectations for the quarter, Moderna’s financial outcomes underscore a notable achievement. Analysts had anticipated an EPS of -$0.98 and revenue projections of $2.51 billion, which the company not only met but surpassed. <br><br>The company’s ability to exceed expectations amidst a challenging market underscores its strong commercial execution and the enduring demand for its COVID-19 vaccine, Spikevax®, despite the industry’s shift towards endemic market dynamics.</p> 
<div class="cta-referral"> 
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async"> 
 <div class="cta-referral__text"> 
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking digital asset story.</a></p> 
 </div> 
</div> 
<h3 id="guidance-for-the-future">Guidance for the Future</h3> 
<p>Moderna remains optimistic about its future trajectory, reaffirming its 2024 expected product sales of approximately $4 billion. The company’s confidence is bolstered by the anticipated regulatory approvals for its investigational RSV vaccine for older adults, starting in the first half of 2024. Moderna is strategically positioned to continue its growth momentum with a pipeline poised for multiple Phase 3 data readouts in the upcoming year. </p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe> 
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p> 
<h3 id="br"><br></h3> 
<p>The post <a rel="nofollow" href="https://tokenist.com/modernas-mrna-unexpected-217-million-profit-marks-a-surprising-q4-achievement/">Moderna’s (MRNA) Unexpected $217 Million Profit Marks a Surprising Q4 Achievement</a> appeared first on <a rel="nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Moderna’s (MRNA) Unexpected $217 Million Profit Marks a Surprising Q4 Achievement

Table of Contents

Tokenist

Other articles published on Feb 22, 2024

Chainway Labs Introduces Citrea, a Groundbreaking Rollup Technology, to Enhance Bitcoin

Smog Price Prediction – Can a Possible CEX Listing Fuel 10x Growth for $SMOG?

Aptos Hints Reversal: Can APT Coin Become MultiBagger Above $15?

Massive Ethereum Whale Makes Surprising Move After ETH Hit $3,000

Hong Kong Attracts 18 Crypto Exchanges for License

Binance Coin Defies Market Weakness, Traders Eye BNB To Hit $400

Join our free newsletter for daily crypto updates!